Table 3.
Multivariable analysis of the association between timing of THR initiation and colorectal cancer risk
| Timing of THR initiation before index date | Case patients (n = 19 449), no. (%) |
Control patients (n = 71 808), no. (%) |
Unadjusted OR (95% CI, P) |
Adjusted OR (95% CI, P)* |
|---|---|---|---|---|
| No thyroid dysfunction and no THR therapy | 18 173 (93.4) | 66 943 (93.2) | Ref. | Ref. |
| 0–6 mo | 77 (0.4) | 213 (0.3) | 1.34 (1.03 to 1.74, P = .03) | 1.31 (1.01 to 1.71, P = .05) |
| 6–12 mo | 98 (0.5) | 323 (0.5) | 1.14 (0.91 to 1.45, P = .26) | 1.11 (0.88 to 1.41, P = .37) |
| 1–5 y | 586 (3.0) | 2,225 (3.1) | 0.95 (0.87 to 1.05, P = .33) | 0.93 (0.85 to 1.03, P = .15) |
| 5–10 y | 402 (2.1) | 1,550 (2.2) | 0.90 (0.80 to 1.01, P = .08) | 0.88 (0.79 to 0.99, P = .03) |
| >10 y | 113 (0.6) | 554 (0.8) | 0.69 (0.56 to 0.85, P = .001) | 0.68 (0.55 to 0.83, P < .001) |
* Adjusted for diabetes mellitus, connective tissue diseases, smoking history, alcohol consumption, chronic use of aspirin/NSAIDs, and performance of screening colonoscopy. Analysis by conditional logistic regression. All statistical tests were two-sided. CI = confidence interval; OR = odds ratio; THR = thyroid hormone replacement.